<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00897728</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000599189</org_study_id>
    <secondary_id>CLCC-IC-COBRED-SEIN</secondary_id>
    <secondary_id>CLCC-IC-2007-11</secondary_id>
    <secondary_id>CLCC-RECF0632</secondary_id>
    <nct_id>NCT00897728</nct_id>
  </id_info>
  <brief_title>Study of Tumor and Blood Samples From Women With Breast Cancer</brief_title>
  <official_title>Colon and Breast Cancer Diagnostics. Clinical Protocol Associated With Cancer of the Breast.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the&#xD;
      laboratory may help doctors learn more about changes that occur in DNA and identify&#xD;
      biomarkers related to cancer.&#xD;
&#xD;
      PURPOSE: This research study is looking at tumor and blood samples from women with breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Assess relapse locally or remotely using biomarkers collected from primary tumor and&#xD;
           blood samples from women with breast cancer during the first 2 years after diagnosis.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate all relapses.&#xD;
&#xD;
        -  Assess survival without relapse.&#xD;
&#xD;
        -  Determine correlation between biomarkers and relapse.&#xD;
&#xD;
      OUTLINE: Primary tumor and blood samples collected during usual care of patients during the&#xD;
      first 2 years after diagnosis are analyzed for biomarkers useful in monitoring and diagnosing&#xD;
      breast cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2008</start_date>
  <primary_completion_date type="Anticipated">February 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Local or remote relapse as assessed by biomarkers in tissue and blood samples collected during the first 2 years after diagnosis</measure>
  </primary_outcome>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of infiltrating unilateral breast cancer&#xD;
&#xD;
               -  No in situ disease (ductal or lobular)&#xD;
&#xD;
               -  No invasive bilateral synchronous disease&#xD;
&#xD;
          -  Breast cancer at high risk, defined by at least 2 of the following factors:&#xD;
&#xD;
               -  Hormone receptor negative (HR-)&#xD;
&#xD;
               -  Axillary node positive&#xD;
&#xD;
               -  Histopathologic grade III&#xD;
&#xD;
               -  High mitotic index (as defined by the Curie Institute as &gt; 20 mitoses per 10&#xD;
                  high-power fields [HPF])&#xD;
&#xD;
               -  Tumor size â‰¥ 2 cm&#xD;
&#xD;
               -  HER2-positive (3 + IHC or FISH/ICHS positive)&#xD;
&#xD;
               -  Triple-negative tumors (HR- and HER2-negative)&#xD;
&#xD;
          -  Initial thoracic-abdomino-pelvic and bone scans must be negative&#xD;
&#xD;
          -  Underwent initial surgery&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  Serum calcium normal (15.3 mg/dL) or normalized within 8 weeks after surgery&#xD;
&#xD;
          -  No other invasive cancer within the past 5 years&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No psychological, familial, social, or geographical reasons that make monitoring&#xD;
             impossible&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul-Henri Cottu</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Curie Hopital</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul-Henri Cottu</last_name>
      <phone>33-3-8393-5005</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>November 30, 2010</last_update_submitted>
  <last_update_submitted_qc>November 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2010</last_update_posted>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>HER2-positive breast cancer</keyword>
  <keyword>triple-negative breast cancer</keyword>
  <keyword>estrogen receptor-negative breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

